EMA Authorised: Rapiscan (regadenoson) — GE Healthcare AS

View source ↗

Summary

The European Medicines Agency authorised Rapiscan, a regadenoson-based diagnostic radiopharmaceutical from GE Healthcare AS, for use in myocardial perfusion ima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease
• Myocardial Ischemia

Drugs mentioned

• Rapiscan (regadenoson)

Snippet

Status: Authorised. Therapeutic area: Myocardial Perfusion Imaging. MAH: GE Healthcare AS. Decision date: 03/09/2025